The phase 3 diabetes endpoint for retatrutide has been met, as shown by TRANSCEND-T2D-1

Retatrutide is a new treatment taken once a week. It activates three receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. The glucagon-receptor component sets it apart from the dual agonists already in use. TRANSCEND-T2D-1 is the first study to show what that combination does for people with diabetes.

TRIAL DESIGN:

• The trial randomised 537 adults with recent-onset type 2 diabetes

• Their average disease duration was around 2.5 years

• These participants had poorly controlled glucose levels despite diet and exercise

• Participants had a baseline HbA1c between 7.0% and 9.5% and a body mass index of at least 23 kg/m².

• They were assigned equally to retatrutide at 4 mg, 9 mg, or 12 mg, or to a placebo. This was given as monotherapy for 40 weeks, with no other glucose-lowering medication.

• Testing the molecule alone, instead of with metformin or other agents, is an unusual choice. This approach makes it easier to link the glycaemic signal to the drug.

RESULTS:

HBA1c

• The primary endpoint was the change in HbA1c at 40 weeks, starting from a baseline of about 7.9%.

• Retatrutide lowered HbA1c by 1.69% on 4 mg, 1.86% on 9 mg and 1.94% on 12 mg, versus a fall of just 0.81% on placebo.

• On the top dose that brought the average down to roughly 6.0%, reported as a reduction of up to 2.0% under the efficacy estimand.

• Around 90% of those on retatrutide reached an HbA1c below the 7.0% target.

• The most common side effects were gastrointestinal issues, mainly nausea, diarrhoea, and vomiting. These were mostly mild to moderate and often went away during treatment.

WEIGHT LOSS:

The weight loss from incretin therapies is usually less in people with type 2 diabetes compared to those with obesity alone. So, these figures are notable in context:

• Participants on the 12 mg dose lost an average of 16.8% of their body weight by week 40. The weight loss trend continued, so it's unclear where their weight might stabilise over time.

• The active arms accompanied the glycaemic and weight effects with reductions in triglycerides, non-HDL cholesterol, systolic blood pressure, and waist circumference.

THE MECHANISM:

The interpretation from the authors (take this with a pinch of salt) is that GIP and GLP-1 help promote insulin, balancing out glucagon's effect of raising glucose. Meanwhile, glucagon aids in energy use and managing liver fat.

That balance is the central premise of a triple agonist, and TRANSCEND-T2D-1 is the first phase 3 evidence that it holds in a diabetes population.

WHAT THIS MEANS FOR PRIMARY CARE:

The trial ran for 40 weeks with people early in their disease. It doesn’t show how long the effects last. It also doesn’t cover those with longstanding or insulin-treated diabetes. Plus, it skips cardiovascular and renal outcomes. These factors are important for guideline decisions.

For UK primary care, these results show a shift towards single molecules. These molecules target multiple metabolic pathways at once. They offer better glycaemic control and more weight loss than traditional type 2 diabetes medications. The next wave of trials needs to find out if that leads to better long-term outcomes and what the cost and tolerability in routine care will be.

Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026;407:892–908. doi:10.1016/S0140-6736(26)00967-0